Mesoblast Ltd
MESO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001345099
No open-market purchases or sales by Mesoblast Ltd insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $53.3M in total; no superinvestor holds it.
Other share classesMEOBF
Q4 2024 vs. Q3 2024
How the institutions holding Mesoblast Ltd changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 43 | 61 | +18 |
| Shares | 1.55M | 3.04M | +1.49M (+96.4%) |
| Value | $12.4M | $59.9M | +$47.5M (+382.3%) |
New holders (26)
Institutions that held Mesoblast Ltd at the end of Q4 2024 but not at the end of Q3 2024.
Sold out (8)
Institutions that held Mesoblast Ltd at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Group One Trading, L.P. | 253,385 | $2.07M |
| Citadel Advisors LLC | 39,968 | $326.5K |
| XY Capital Ltd | 29,850 | $243.9K |
| Two Sigma Investments, LP | 20,351 | $166.3K |
| Marshall Wace, LLP | 17,723 | $144.8K |
| Millennium Management LLC | 14,664 | $119.8K |
| Perkins Coie Trust Co | 11,500 | $94.0K |
| Ronald Blue Trust, Inc. | 146 | $994 |